Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. cut its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,428 shares of the medical equipment provider’s stock after selling 379 shares during the period. Crossmark Global Holdings Inc.’s holdings in Intuitive Surgical were worth $7,229,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ISRG. Baystate Wealth Management LLC raised its stake in Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 45 shares in the last quarter. MCF Advisors LLC boosted its holdings in Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 40 shares during the period. Headinvest LLC bought a new stake in Intuitive Surgical during the third quarter valued at $28,000. Stone House Investment Management LLC raised its holdings in shares of Intuitive Surgical by 100.0% during the third quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 50 shares during the period. Finally, Truvestments Capital LLC lifted its position in shares of Intuitive Surgical by 137.2% in the 3rd quarter. Truvestments Capital LLC now owns 102 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 59 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on ISRG. Piper Sandler increased their price objective on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research note on Friday, April 19th. The Goldman Sachs Group assumed coverage on Intuitive Surgical in a research report on Thursday, May 30th. They set a “buy” rating and a $500.00 price objective for the company. StockNews.com lowered Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Robert W. Baird lowered their price target on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research report on Friday, April 19th. Finally, BTIG Research boosted their target price on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research note on Friday, April 19th. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and an average price target of $403.67.

Insider Transactions at Intuitive Surgical

In other news, SVP Mark Brosius sold 175 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $389.16, for a total value of $68,103.00. Following the completion of the sale, the senior vice president now directly owns 883 shares of the company’s stock, valued at $343,628.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Robert Desantis sold 20,296 shares of the company’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $393.80, for a total value of $7,992,564.80. Following the completion of the transaction, the executive vice president now directly owns 5,507 shares in the company, valued at $2,168,656.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mark Brosius sold 175 shares of Intuitive Surgical stock in a transaction on Monday, May 13th. The stock was sold at an average price of $389.16, for a total transaction of $68,103.00. Following the sale, the senior vice president now owns 883 shares in the company, valued at approximately $343,628.28. The disclosure for this sale can be found here. Over the last three months, insiders sold 40,779 shares of company stock worth $15,862,204. 0.80% of the stock is owned by insiders.

Intuitive Surgical Price Performance

NASDAQ:ISRG traded up $10.63 during trading hours on Wednesday, reaching $417.24. The company’s stock had a trading volume of 2,226,502 shares, compared to its average volume of 1,526,433. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $418.14. The business’s 50-day moving average is $387.88 and its 200-day moving average is $368.84. The company has a market cap of $148.00 billion, a price-to-earnings ratio of 73.40, a price-to-earnings-growth ratio of 5.22 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.00 EPS. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.